Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-T cells + XELOX + Bevacizumab in mCRC
NCT03950154Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Aug 2023
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PD1-T cells in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival at 3 years. Status: unknown.
02
Drugs
PD1-T cells
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03950154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950154.